Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TRIM24 | O15164 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11682254 | 0.90 | SMN1; SMN2 (0.70) | SMN1; SMN2MAPTNPC1TP53RAB9A | |
| SCHEMBL14067268 | 0.86 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPTNPC1TP53RAB9A | |
| SCHEMBL13002857 | 0.85 | NOTUM (0.65) | SMN1; SMN2MAPTNPC1TP53RAB9A | |
| SCHEMBL14067050 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTNPC1TP53RAB9A | |
| SCHEMBL854030 | 0.82 | ALDH1A1 (0.63) | SMN1; SMN2MAPTNPC1TP53RAB9A | |
| SCHEMBL5781313 | 0.82 | NOTUM (0.57) | SMN1; SMN2MAPTNPC1TP53RAB9A | |
| SCHEMBL9045231 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTNPC1TP53RAB9A | |
| SCHEMBL8649563 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTNPC1TP53RAB9A | |
| SCHEMBL14590670 | 0.81 | TP53 (0.60) | SMN1; SMN2MAPTNPC1TP53RAB9A | |
| SCHEMBL14148139 | 0.81 | NOTUM (0.60) | SMN1; SMN2MAPTNPC1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | SMN1; SMN2 2454/4885MAPT 3805/4885NPC1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.